Akira Sezai 1, Satoshi Unosawa 1, Makoto Taoka 1, Shunji Osaka 1, Hisakuni Sekino 2, Masashi Tanaka 1
Main idea: Febuxostat had stronger renoprotective and antioxidant effects than topiroxostat in patients with hyperuricemia and chronic kidney disease.
Background: The TROFEO trial demonstrated that febuxostat causes a greater and more rapid reduction of serum uric acid (s-UA) than topiroxostat. We compared these drugs in patients with chronic kidney disease (CKD) by sub-analysis of the TROFEO trial.
Methods: This sub-analysis targeted patients with an estimated glomerular filtration rate (eGFR) The primary endpoint was the s-UA level. Secondary endpoints included creatinine, eGFR, urinary albumin, cystatin-C, and oxidized low-density lipoprotein.
Results: There was no significant difference of s-UA between the two groups either before or after treatment. Serum creatinine (s-Cr) and eGFR were significantly better after 6 months of febuxostat treatment compared with topiroxostat. The Ox-LDL was significantly lower after 3 and 6 months.